CureDuchenne Appoints Dr. Brenda Wong to Lead Medical Research for Duchenne Muscular Dystrophy

CureDuchenne Appoints Dr. Brenda Wong as Chief Medical Advisor

CureDuchenne, a prominent global nonprofit organization dedicated to finding a cure for Duchenne muscular dystrophy (DMD), has made a significant leadership appointment with Dr. Brenda Wong, MD, stepping in as Chief Medical Advisor. This move, effective January 5, 2026, is expected to advance the organization’s commitment to improving research and care for individuals affected by both Duchenne and Becker muscular dystrophy.

Dr. Wong is a respected authority in the fields of neuromuscular medicine and clinical research. She has dedicated her career to providing compassionate, patient-centered care for those struggling with these challenges. With over two decades of expertise in pediatrics and an extensive 25-year background in pediatric neurology, Dr. Wong has positioned herself as a leading figure in the field. Previously, she oversaw the Comprehensive Neuromuscular Center at Cincinnati Children’s Hospital Medical Center for 19 years, before moving to Massachusetts to found the Duchenne Muscular Dystrophy Center at UMass Memorial Medical Center.

As she assumes her new role at CureDuchenne, Dr. Wong will be instrumental in shaping clinical strategies. She will ensure that CureDuchenne’s programs and partnerships consistently uphold the highest standards in terms of patient-focused care and therapeutic advancement. One of her core missions will be to empower families impacted by these muscular dystrophies, providing them with the necessary support and guidance as they navigate this complex landscape.

Dr. Wong’s collaboration will extend across the medical and research sectors, working closely with pharmaceutical and biotech companies to offer insightful strategies regarding clinical trial frameworks. Her expertise will also play a pivotal role in enhancing standards of care, aligning them with the evolving needs of the Duchenne community worldwide.

Debra Miller, the founder and CEO of CureDuchenne, expressed her enthusiasm about Dr. Wong’s arrival, emphasizing the significance of her clinical insight and leadership. Miller stated, "Welcoming Dr. Wong to CureDuchenne is both an honor and a pivotal moment for our organization. Her experience and compassionate nature fit seamlessly with our mission. With her guidance, we are better equipped than ever to drive breakthroughs and raise the standards of care for families affected by these conditions."

Dr. Wong herself shared her excitement for joining CureDuchenne, expressing, "I am very excited to join CureDuchenne for the next chapter of my advocacy. I look forward to helping accelerate the development and accessibility of transformative therapies for the Duchenne and Becker muscular dystrophy community."

Looking ahead, Dr. Wong is set to share her vast knowledge at the upcoming CureDuchenne 2025 FUTURES National Conference, taking place in San Antonio from May 22-25, 2025. At this conference, she will lead discussions aimed at navigating the dynamic landscape of Duchenne and Becker therapies, as well as addressing specific needs concerning women with dystrophinopathy and the everyday challenges that individuals and families face.

CureDuchenne was established 20 years ago with the singular goal of finding and funding a cure for Duchenne muscular dystrophy, one of the most severe forms of muscular dystrophy. Over the years, it has emerged as a global leader in research and patient care, pioneering various initiatives, including a groundbreaking venture philanthropy model that has facilitated numerous clinical trials aimed at combating Duchenne muscular dystrophy.

For more information on how to support CureDuchenne’s mission or to learn more about Duchenne muscular dystrophy, please visit their official website, or follow them across various social media platforms such as Facebook, Instagram, LinkedIn, and X.